Nahkuri Satu, Becker Tim, Schueller Vitalia, Massberg Steffen, Bauer-Mehren Anna
Data Science, Pharma Research and Development, Roche Innovation Center Zurich, Zurich, Switzerland.
Data Science, Pharma Research and Development, Roche Innovation Center Munich, Munich, Germany.
Commun Med (Lond). 2021 Nov 25;1:51. doi: 10.1038/s43856-021-00051-x. eCollection 2021.
The COVID-19 pandemic represents a major public health threat. Risk of death from the infection is associated with age and pre-existing comorbidities such as diabetes, dementia, cancer, and impairment of immunological, hepatic or renal function. It remains incompletely understood why some patients survive the disease, while others do not. As such, we sought to identify novel prognostic factors for COVID-19 mortality.
We performed an unbiased, observational retrospective analysis of real world data. Our multivariable and univariable analyses make use of U.S. electronic health records from 122,250 COVID-19 patients in the early stages of the pandemic.
Here we show that a priori diagnoses of fluid, pH and electrolyte imbalance during the year preceding the infection are associated with an increased risk of death independently of age and prior renal comorbidities.
We propose that future interventional studies should investigate whether the risk of death can be alleviated by diligent and personalized management of the fluid and electrolyte balance of at-risk individuals during and before COVID-19.
2019冠状病毒病(COVID-19)大流行是一项重大的公共卫生威胁。感染导致的死亡风险与年龄以及诸如糖尿病、痴呆症、癌症等既存合并症,还有免疫、肝脏或肾脏功能损害有关。为何一些患者能从该疾病中存活下来,而另一些患者却不能,目前仍未完全明确。因此,我们试图确定COVID-19死亡的新预后因素。
我们对真实世界数据进行了无偏倚的观察性回顾分析。我们的多变量和单变量分析利用了大流行早期122250例COVID-19患者的美国电子健康记录。
我们在此表明,在感染前一年对液体、pH值和电解质失衡的先验诊断与死亡风险增加相关,且独立于年龄和既往肾脏合并症。
我们建议未来的干预性研究应调查在COVID-19期间及之前,对高危个体的液体和电解质平衡进行勤勉且个性化的管理是否能够降低死亡风险。